Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML October 21, 2025
Initial clinical data on the combination of AB8939 + venetoclax in the first three patients with R/R AML announced October 15, 2025
Pivotal Ziftomenib Data in R/R NPM1-Mutated AML Published in the Journal of Clinical Oncology September 30, 2025
Revuforj® (revumenib) Included in NCCN Guidelines for the Treatment of R/R NPM1 Mutated AML September 23, 2025
Jaypirca significantly improved PFS in patients with treatment-naïve CLL/SLL in the Ph 3 BRUIN CLL-313 study September 9, 2025
CHARM Therapeutics raises $80M in Series B financing to advance development of menin inhibitor for AML September 3, 2025
Early Data Demonstrates Tuspetinib Improves SOC Treatment Across Diverse Populations of Newly Diagnosed AML in Ph 1/2 TUSCANY Trial August 19, 2025
Patient deaths trigger discontinuation of Ph 1 trial from SGR-2921 Program in R/R AML and HR-MDS patients August 19, 2025
NeOnc Technologies Awarded $2.5M in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia in Ph 2 trials August 12, 2025
Enrollment Open for 160 mg Dosing Cohort of Tuspetinib in Ph 1/2 TUSCANY Trial of 1L Triple Drug Therapy in induction-ineligible AML patients August 12, 2025
RP2D in Ph 1 Study of SENTI-202 for the Treatment of R/R Heme Malignancies, Including AML, Determined August 12, 2025
Supplemental NDA submitted to FDA for fixed-duration, all-oral combo regimen of VENCLEXTA and acalabrutinib in 1L CLL patients August 5, 2025
Jaypirca (pirtobrutinib) met primary endpoint in a head-to-head Ph 3 trial versus Imbruvica (ibrutinib) in CLL/SLL August 5, 2025
Approval of the third of four stages of the Ph 1/2 study of AB8939 in R/R AML patients announced August 5, 2025
